Medtronic, Inc. To Pursue Pivotal Trials Of Treatments For Overactive Bladder And Enlarged Prostate

MINNEAPOLIS--(BUSINESS WIRE)--May 22, 2006--Medtronic, Inc. (NYSE:MDT - News), today announced its intentions to pursue two separate pivotal trials of the company’s commercially available urological therapies: InterStim Therapy for Urinary Control, a treatment for overactive bladder and urinary retention; and PROSTIVA(TM) RF Therapy, a treatment for symptomatic benign prostatic hyperplasia (BPH).